Dovato

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Dovato treats HIV (human immunodeficiency virus). Test for hepatitis B before taking Dovato.

Dovato Overview

Reviewed: April 26, 2019
Updated: 

Dovato is a prescription medication used to treat HIV (human immunodeficiency virus). HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS).

Dovato is a single product containing 2 medications: dolutegravir and lamivudine. Dolutegravir belongs to a group of drugs called integrase strand transfer inhibitors [INSTIs]. Lamivudine belongs to a group of drugs called nucleoside analogue reverse transcriptase inhibitors [NRTIs]. These two drugs inhibit the viral cycle at two different sites, which stops the virus from multiplying. 

Dovato comes in tablet form and is taken by mouth, once daily, at the same time every day. It can be taken with our without food.

Common side effects include headache, diarrhea, nausea, trouble sleeping, and tiredness.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Dovato Drug Class

Back to Top

Dovato FDA Warning

Back to Top

WARNING: PATIENTS CO-INFECTED WITH HEPATITIS B VIRUS (HBV) AND HUMAN IMMUNODEFICIENCY VIRUS (HIV-1): EMERGENCE OF LAMIVUDINERESISTANT HBV AND EXACERBATIONS OF HBV

All patients with HIV-1 should be tested for the presence of HBV prior to or when initiating DOVATO. Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported. If DOVATO is used in patients co-infected with HIV-1 and HBV, additional treatment should be considered for appropriate treatment of chronic HBV; otherwise, consider an alternative regimen.

Severe acute exacerbations of HBV have been reported in patients who are co-infected with HIV-1 and HBV and have discontinued lamivudine, a component of DOVATO. Closely monitor hepatic function in these patients and, if appropriate, initiate anti-HBV treatment.